AVX-70120 is under clinical development by AstriVax and currently in Phase I for Yellow Fever. According to GlobalData, Phase I drugs for Yellow Fever does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the AVX-70120 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AVX-70120 overview
AstriVax overview
AstriVax is an innovative vaccine platform company that develops prophylactic and therapeutic vaccines. The company’s pipeline products comprise yellow fever vaccine, rabies vaccine and chronic hepatitis B vaccine and therapeutic human papillomavirus (HPV) vaccine. It uses DNA-based technology that launches self-amplifying live attenuated viruses, resulting in polyfunctional and vigorous nature of the immune response to develop the plasmid-launched live attenuated virus (PLLAV) platform. AstriVax is headquartered in Leuven, Flemish Brabant, Belgium.
For a complete picture of AVX-70120’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
